Abstract
Recently developed multi-targeted ligands are novel drug candidates able to interact with monoamine oxidase A and B; acetylcholinesterase and butyrylcholinesterase; or with histamine N-methyltransferase and histamine H3-receptor (H3R). These proteins are drug targets in the treatment of depression, Alzheimer’s disease, obsessive disorders, and Parkinson’s disease. A probabilistic method, the Parzen–Rosenblatt window approach, was used to build a “predictor” model using data collected from the ChEMBL database. The model can be used to predict both the primary pharmaceutical target and off-targets of a compound based on its structure. Molecular structures were represented based on the circular fingerprint methodology. The same approach was used to build a “predictor” model from the DrugBank dataset to determine the main pharmacological groups of the compound. The study of off-target interactions is now recognised as crucial to the understanding of both drug action and toxicology. Primary pharmaceutical targets and off-targets for the novel multi-target ligands were examined by use of the developed cheminformatic method. Several multi-target ligands were selected for further study, as compounds with possible additional beneficial pharmacological activities. The cheminformatic targets identifications were in agreement with four 3D-QSAR (H3R/D1R/D2R/5-HT2aR) models and by in vitro assays for serotonin 5-HT1a and 5-HT2a receptor binding of the most promising ligand (71/MBA-VEG8).
Similar content being viewed by others
Abbreviations
- AD:
-
Alzheimer’s disease
- AChE:
-
Acetylcholinesterase
- BuChE:
-
Butyrylcholinesterase
- CFP:
-
Circular fingerprint
- 3D-QSAR:
-
3D-Quantitive structure–activity relationship
- EDTA:
-
Ethylenediaminetetraacetic acid
- FP:
-
False positive
- GSK-3:
-
Glycogen synthase kinase 3
- HMT:
-
Histamine N-methyltransferase
- H3R:
-
Histamine H3-receptor
- 5-HT1a :
-
5-Hydroxytryptamine-1a (serotonin)
- 5-HT2a :
-
5-Hydroxytryptamine-2a (serotonin)
- 5-HT2c :
-
5-Hydroxytryptamine-2c (serotonin)
- MAO-A:
-
Monoamine oxidase A
- MAO-B:
-
Monoamine oxidase B
- MCC:
-
Matthews correlation coefficient
- MTDL:
-
Multi-target-directed ligand
- NMDA receptors:
-
N-Methyl-d-aspartate receptor
- nAChRs:
-
Nicotinic acetylcholine receptors
- 8-OH-DPAT:
-
(±)-8-Hydroxy-2-dipropylaminotetralin
- PDE-4:
-
Phosphodiesterase 4
- PD:
-
Parkinson’s disease
- RMSEE:
-
Root main square error of estimation
- RMSEP:
-
Root main square error of prediction
- SERT:
-
Serotonin transporter
- TP:
-
True positive
- Tris:
-
Tris(hydroxymethyl)aminomethane
- WADA:
-
World Anti-Doping Agency
References
Goedert M, Spillantini MGA (2006) A century of Alzheimer’s disease. Science 314:777–781
Humbert-Claude M, Morisset S, Gbahou F, Arrang JM (2007) Histamine H3 and dopamine D2 receptor-mediated [35S]GTPγ[S] binding in rat striatum: evidence for additive effects but lack of interactions. Biochem Pharmacol 73:1172–1181
Garduno-Torres B, Trevino M, Gutierrez R, Arias-Montano JA (2007) Presynaptic histamine H3 receptors regulate glutamate, but not GABA release in rat thalamus. Neuropharmacology 52:527–535
Dai H, Fu Q, Shen Y, Hu W, Zhang Z, Timmerman H, Leurs R, Chen Z (2007) The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons. Eur J Pharmacol 563:117–123
Threlfell S, Cragg SJ, Imre K, Turi GF, Coen CW, Greenfield SA (2004) Histamine H3 receptors inhibit serotonin release in substantia nigra pars reticulata. J Neurosci 24:8704–8710
Gemkow MJ, Davenport AJ, Harich S, Ellenbroek BA, Cesura A, Hallett D (2009) The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today 14:509–515
León R, Garcia AG, Marco-Contelles J (2013) Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev 33:139–189
Millan MJ (2014) On ‘polypharmacy’ and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. Int J Neuropsychopharmacol 17:1009–1037
Anighoro A, Bajorath J, Rastelli G (2014) Polypharmacology: challenges and opportunities in drug discovery. J Med Chem 57:7874–7887
Morphy R, Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48:6523–6543
Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353–359
Lipina TV, Palomo V, Gil C, Martinez A, Roder JC (2013) Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology 64:205–214
Lipina TV, Wang M, Liu F, Roder JC (2012) Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice. Neuropharmacology 62:1252–1262
Millan MJ (2006) Multi-target strategies for the improved treatment of depressive states: conceptual foundation and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110:135–370
Meltzer HY, Massey BW, Horiguchi M (2012) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 13:1572–1586
Quesseveur G, Nguyen HT, Gardier AM, Guiard BP (2012) 5-HT2 ligands in the treatment of anxiety and depression. Expert Opin Investig Drugs 21:1701–1725
Youdim MBH, Buccafusco JJ (2005) Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26:27–35
Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E, Cochet C, Schmid RS, Lo DC, Delhommel F, Oberholzer AE, Pearl LH, Carreaux F, Bazureau JP, Knapp S, Meijer L (2012) Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem 55:9312–9330
Rosini M, Antonello A, Cavalli A, Bolognesi ML, Minarini A, Marucci G, Poggesi E, Leonardi A, Melchiorre C (2003) Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for α1-adrenoreceptors. J Med Chem 46:4895–4903
Fang L, Appenroth D, Decker M, Kiehntopf M, Roegler C, Deufel T, Fleck C, Peng S, Zhang Y, Lehmann J (2008) Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J Med Chem 51:713–716
Stosel A, Schlenk M, Hinz S, Kuppers P, Heer J, Gutschow M, Muller CE (2013) Dual targeting of adenosine A2A receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones. J Med Chem 56:4580–4596
Fang L, Kraus B, Lehmann J, Heilmann J, Zhang Y, Decker M (2008) Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg Med Lett 18:2905–2909
Jiménez JJ, Mendes E, Galdeano C, Martins C, Silva DB, Marco-Contelles J, Carmo Carreiras M, Luque FJ, Ramsay RR (2014) Exploring the structural basis of the selective inhibition of monoamine oxidase A by dicarbonitrile aminoheterocycles: role of Asn181 and Ile335 validated by spectroscopic and computational studies. Biochim Biophys Acta 1844:389–397
Bautista-Aguileraa OM, Estebanb G, Bolea I, Nikolic K, Agbaba D, Moraleda I, Iriepa I, Samadi A, Soriano E, Unzeta M, Marco-Contelles J (2014) Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil–indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer’s disease. Eur J Med Chem 75:82–95
Samadi A, Chioua M, Bolea I, de los Ríos C, Iriepa I, Moraleda I, Bastida A, Esteban G, Unzeta M, Gálvez E, Marco-Contelles J (2011) Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer’s disease. Eur J Med Chem 46:4665–4668
Bolea I, Juárez-Jiménez J, Ríos C, Chioua M, Pouplana R, Javier Luque F, Unzeta M, Marco-Contelles J, Samadi A (2011) Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease. J Med Chem 54:8251–8270
Pérez V, Marco-Contelles J, Fernández-Álvarez E, Unzeta M (1999) Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br J Pharmacol 127:869–876
Marco-Contelles J, Leon R, Rıos C, Guglietta A, Terencio J, Lopez MG, Garcıa AG, Villarroya M (2006) Novel multipotent tacrine–dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer’s disease. J Med Chem 49(26):7607–7610
Marco-Contelles J, Leon R, Rıos C, Samadi A, Bartolini M, Andrisano V, Huertas O, Barril X, Luque FJ, Rodrıguez-Franco MI, Lopez B, Lopez MG, Garcıa AG, Carmo Carreiras M, Villarroya M (2009) Tacripyrines, the first tacrine–dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer’s disease. J Med Chem 52:2724–2732
Apelt J, Ligneau X, Pertz H, Arrang JM, Ganellin CR, Schwartz JC, Schunack W, Holger S (2002) Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity. J Med Chem 45:1128–1141
Petroianu G, Arafat K, Sasse BC, Stark H (2006) Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents. Pharmazie 61:179–182
Grassmann S, Apelt J, Sippl W, Ligneau X, Pertz HH, Zhao YH, Arrang JM, Ganellin CR, Schwartz JC, Schunack W, Stark H (2003) Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine H3 receptor affinities. Bioorg Med Chem 11:2163–2174
Grassmann S, Apelt J, Ligneau X, Pertz HH, Arrang JM, Schwartz JC, Schunack W, Stark H (2004) Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: omega-piperidinoalkanamine derivatives. Arch Pharm Med Chem 337:533–545
Apelt J, Grassmann S, Ligneau X, Pertz HH, Ganellin CR, Arrang JM, Schwartz JC, Schunack W, Stark H (2005) Search for histamine H3 receptor antagonists with combined inhibitory potency at Ntau-methyltransferase: ether derivatives. Pharmazie 60:97–106
Ligneau X, Lin JS, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz JC (1998) Neurochemical and behavioural effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 287:658–666
Sander K, Kottke T, Stark H (2008) Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 31:2163–2181
Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD (2008) The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 154:1166–1181
Di Giovanni G, Di Matteo V, Pierucci M, Esposito E (2008) Serotonin–dopamine interaction: electrophysiological evidence. Prog Brain Res 172:45–71
Di Matteo V, Di Giovanni G, Pierucci M, Esposito E (2008) Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog Brain Res 172:7–44
Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson ‘s disease. Trends Neurosci 13:272–276
Millan MJ (2005) N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179:30–53
Rogawski MA, Wenk GL (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev 9:275–308
Cummings JL, Morstorf T, Zhong K (2014) Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6:37
Zheng H, Youdim MBH, Fridkin M (2009) Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer’s therapy. J Med Chem 52:4095–4098
Cavalli A, Bolognesi ML, Minarini M, Rosini V, Tumiatti M, Recanatini C, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51:347–372
Cannon EO, Bender A, Palmer DS, Mitchell JBO (2006) Chemoinformatics-based classification of prohibited substances employed for doping in sport. J Chem Inf Model 5:2369–2380
Cannon EO, Mitchell JBO (2006) Classifying the World Anti-Doping Agency’s 2005 prohibited list using the chemistry development kit fingerprint. Lect Notes Bioinform 5:173–182
Cannon EO, Nigsch F, Mitchell JBO (2008) Novel hybrid ultrafast shape descriptor method for use in virtual screening. Chem Central J 5:3
Paolini VG, Shapland RHB, Van Hoorn WP, Mason JS, Hopkins AL (2006) Global mapping of pharmacological space. Nat Biotechnol 5:805–815
Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL (2007) Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. Chem Med Chem 5:861–873
Nigsch F, Mitchell JBO (2008) Toxicological relationships between proteins obtained from protein target predictions of large toxicity databases. Toxicol Appl Pharmacol 5:225–234
Nigsch F, Bender A, Jenkins JL, Mitchell JBO (2008) Ligand-target prediction using winnow and naive bayesian algorithms and the implications of overall performance statistics. J Chem Inf Model 5:2313–2325
Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KLH, Edwards DD, Shoichet BK, Roth BL (2009) Predicting new molecular targets for known drugs. Nature 5:175–181
Niijima S, Yabuuchi H, Okuno Y (2011) Cross-target view to feature selection: identification of molecular interaction features in ligand-target space. J Chem Inf Model 5:15–24
Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Lavan P, Weber E, Doak AK, Cote S, Shoichet BK, Urban L (2012) Large-scale prediction and testing of drug activity on side-effect targets. Nature 5:361–367
Perez-Nueno VI, Venkatraman V, Mavridis L, Ritchie DW (2012) Detecting drug promiscuity using gaussian ensemble screening. J Chem Inf Model 5:1948–1961
Glen RC, Bender A, Arnby CH, Carlsson L, Boyer S, Smith J (2006) Circular fingerprints: flexible molecular descriptors with applications from physical chemistry to ADME. IDrugs 9:199–204
Mavridis L, Mitchell JBO (2013) Predicting the protein targets for athletic performance-enhancing substances. J Cheminform 5:31
Gaulton A, Bellis LJ, Bento PA, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucl Acids Res 5:D1100–D1107
Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Whishart DS (2011) DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs. Nucl Acids Res 5:D1035–D1041
Mavridis L, Nath N, Mitchell JBO (2013) PFClust: a novel parameter free clustering algorithm. BMC Bioinform 14:213
Rogers DJ, Tanimoto TT (1960) A computer program for classifying plants. Science 5:1115–1118
Parzen E (1962) On estimation of a probability density function and mode. Ann Math Statist 5:1065–1076
Rosenblatt M (1956) Remarks on some nonparametric estimates of a density function. Ann Math Statist 5:832–837
Matthews BW (1975) Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim Biophys Acta 5:442–451
Hamacher A, Weigt M, Wiese M, Hoefgen B, Lehmann J, Kassack MU (2006) Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis. BMC Pharmacol 6:11
ChemAxon MarvinSketch 5.5.1.0 program (2011) Budapest, Hungary. www.chemaxon.com/products.html
Froese Fischer CF (1977) The Hartree–Fock method for atoms: a numerical approach. Wiley, New York
Frisch MJ et al (1998) Gaussian 98 (Revision A.7). Gaussian Inc., Pittsburgh
Pentacle, Version 1.0.6. (2009) Molecular Discovery Ltd., Perugia, Italy. http://www.moldiscovery.com/soft_pentacle.php
Eriksson L, Johansson E, Kettaneh-Wold N, Trygg J, Wikstrom C, Wold S (eds) (2001) Multi-and megavariate data analysis. Basic principles and applications I, 2nd edn. Umetrics Academy, Umeå
Tropsha A (2010) Best practices for QSAR model development, validation, and exploitation. Mol Inf 29:476–488
Cheng YC, Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108
Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:660–672
Schlegel JR, Peroutka SJ (1986) Nucleotide interactions with 5-HT1A binding sites directly labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT). Biochem Pharmacol 35:1943–1949
Herndon JL, Ismaiel A, Ingher SP, Teitler M, Glennon RA (1992) Ketanserin analogues: structure–affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem 35:4903–4910
Buhot MC, Martin S, Segu L (2000) Role of serotonin in memory impairment. Ann Med 32:210–221
Roth BL, Hanizavareh SM, Blum AE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 174:17–24
Gray JA, Roth BL (2007) The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12:904–922
Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A (2009) Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 70:829–836
Patat A, Parks V, Raje S, Plotka A, Dietrich B (2005) Age–gender study of SRA-333, a novel 5-HT1A antagonist. Clin Pharmacol Ther 77:P29
Pitsikas N, Tsitsirigou S, Zisopoulou S, Sakellaridis N (2005) The 5-HT1A receptor and recognition memory. Possible modulation of its behavioral effects by the nitrergic system. Behav Brain Res 159:287–293
Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M, Barrett JE, Childers W (2005) Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther 314:1274–1289
Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, Tremblay L, Sgambato-Faure V, Broussolle E, Thobois S (2012) Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson’s disease. Mov Disord 27:84–89
Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG (2011) Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav 99:130–145
Terry AV Jr, Buccafusco JJ, Bartoszyk GD (2005) Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. Psychopharmacology 179:725–732
Onogi H, Ishigaki S, Nakagawasai O, Arai-Kato Y, Arai Y, Watanabe H, Miyamoto A, Tan-No K, Tadano T (2009) Influence of memantine on brain monoaminergic neurotransmission parameters in mice: neurochemical and behavioral study. Biol Pharm Bull 32:850–855
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ (2006) A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 63:49–54
Kim HS, Park IS, Park WK (1998) NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in mice. Life Sci 63:2305–2311
Nakagawasai O, Arai Y, Satoh SE, Satoh N, Neda M, Hozumi M, Oka R, Hiraga H, Tadano T (2004) Monoamine oxidase and head-twitch response in mice mechanisms of α-methylated substrate derivatives. Neurotoxicology 25:223–232
Raddatz R, Tao M, Hudkins RL (2010) Histamine H3 antagonists for treatment of cognitive deficits in CNS diseases. Curr Top Med Chem 10:153–169
Acknowledgments
This project has been carried out with the support of WADA. We also acknowledge financial support from the Scottish Universities Life Sciences Alliance (SULSA). OMBA and JMC thenk MINECO (Spain) for a fellowship, and support (SAF2012-33304), respectively. KN and DA acknowledge project supported by the Ministry of Education and Science of the Republic of Serbia, Contract No. 172033. Further supports by Else Kröner-Fresenius-Stiftung, Translational Research Innovation—Pharma (TRIP), Fraunhofer-Projektgruppe für Translationale Medizin und Pharmakologie (TMP) (to HS) and the European COST Actions BM1007, CM1103 (including STSM 10295 to KN), and CM1207 are also gratefully acknowledged.
Conflict of interest
The authors (JBOM, LM) have received funding from WADA. Other then this sponsorship, the authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
10822_2014_9816_MOESM1_ESM.tif
Supplementary Figure 1: Ligand-pharmacological group associations for all examined compounds (1–134), obtained by querying the 134 compounds against the refined DrugBank dataset (TIFF 14384 kb)
10822_2014_9816_MOESM2_ESM.xls
Supplementary Table 1: Ligand-target associations for all examined compounds (1–134), obtained by querying the 134 compounds against the refined ChEMBL dataset (XLS 466 kb)
10822_2014_9816_MOESM3_ESM.xls
Supplementary Table 2: Ligand-pharmacological group associations for all examined compounds (1–134), obtained by querying the 134 compounds against the refined DrugBank dataset (XLS 546 kb)
Rights and permissions
About this article
Cite this article
Nikolic, K., Mavridis, L., Bautista-Aguilera, O.M. et al. Predicting targets of compounds against neurological diseases using cheminformatic methodology. J Comput Aided Mol Des 29, 183–198 (2015). https://doi.org/10.1007/s10822-014-9816-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-014-9816-1